Genelux Corporation Expands Leadership Team
Genelux Corporation, a prominent player in the field of immuno-oncology, has expanded its executive leadership by announcing the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer, and Head of Business Development.
New Leadership Brings Valuable Experience
Located in the heart of California's thriving biotech scene, Genelux Corporation is thrilled to welcome Eric Groen to its team. His effective start date for these roles is set for the first of July. As highlighted by Thomas Zindrick, President and CEO of Genelux, Eric's legal adeptness paired with his comprehensive experience in global business development are assets that will significantly advance the company’s strategic objectives.
An Impressive Track Record
Eric Groen is no stranger to the life sciences arena, bringing over 20 years of executive experience to Genelux. His past roles have empowered him to drive significant results, foster collaborative teams, and enhance corporate culture. His passion lies in advancing healthcare innovation, and he is particularly excited about the potential of Olvi-Vec, a groundbreaking treatment that could offer new hope to patients.
Prior Experience Sets the Stage for Success
Before joining Genelux, Groen served as General Counsel for Rani Therapeutics, which is also a clinical-stage biotech company. His impressive tenure at Amgen further solidifies his credibility, where he was integral to major transactions, including a notable $10 billion acquisition. Groen holds a Juris Doctor from Harvard Law School and a Bachelor's degree from UC Santa Barbara.
Driving Change at Genelux
Groen expressed his enthusiasm upon joining Genelux, stating, "I'm honored to join at such a pivotal time. This company has a clear and inspiring vision, compelling science, and a strategic path forward. I'm eager to work with the team to spearhead growth initiatives and broaden our collaborative efforts globally." His leadership is expected to greatly influence the ongoing research and development of Olvi-Vec, addressing needs for innovative treatment options.
Stock Options and Incentives
In recognition of his new role, Groen was granted an inducement award under Genelux's 2023 Inducement Plan which entails a stock option to purchase 270,000 shares of common stock at an exercise price of $2.83 per share. This award is designed to vest over four years as a testament to his commitment and long-term engagement with the company.
About Genelux Corporation
Genelux Corporation is steadfast in its dedication to developing advanced biopharmaceutical therapies for patients battling difficult-to-treat cancers. Their flagship candidate, Olvi-Vec, showcases the company’s innovative approach using a modified vaccinia virus strain aimed at treating solid tumor types effectively. Currently undergoing Phase 3 trials, Olvi-Vec's potential impact marks a significant milestone in targeted immunotherapy.
Harnessing the CHOICE™ Platform
The core of Genelux’s efforts is its proprietary CHOICE™ platform, which enables the creation of a diverse library of engineered oncolytic virus therapies, each with unique therapeutic capabilities aimed at enhancing patient outcomes. This strategic focus not only sets Genelux apart but also underscores their commitment to advancing cancer treatment options for those in need.
Frequently Asked Questions
What is the role of Eric Groen at Genelux Corporation?
Eric Groen has been appointed as General Counsel, Corporate Secretary, Chief Compliance Officer, and Head of Business Development.
What notable experience does Eric Groen bring to Genelux?
He offers over 20 years in life sciences, with significant roles at Rani Therapeutics and Amgen, where he led major transactions.
What is Olvi-Vec?
Olvi-Vec is Genelux’s advanced candidate focused on treating difficult-to-address solid tumor cancers.
How does Genelux plan to achieve its growth strategy?
Under Groen’s leadership, Genelux aims to enhance partnerships and strategic growth initiatives worldwide, focusing on innovative treatment options.
What is the significance of the CHOICE™ platform for Genelux?
The CHOICE™ platform helps Genelux develop a diverse library of oncolytic virus therapies, enhancing their therapeutic offerings.
